These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15329041)

  • 21. Intravenous lansoprazole: in erosive oesophagitis.
    Dando TM; Plosker GL
    Drugs; 2004; 64(18):2085-9; discussion 2090. PubMed ID: 15341501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
    Russo A; Dattilo M
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
    Avner DL; Movva R; Nelson KJ; McFarland M; Berry W; Erfling W
    Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
    Vakily M; Amer F; Kukulka MJ; Andhivarothai N
    J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of gastric ulcer healing by lansoprazole by measurement of ulcer diameter.
    Aoyama N; Kinoshita Y; Misaki F; Himeno S; Kasuga M; Chiba T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S86-9. PubMed ID: 7594351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
    Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
    Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ
    Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage.
    Singh G; Triadafilopoulos G
    Int J Clin Pract; 2005 Oct; 59(10):1210-7. PubMed ID: 16178990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists.
    Kovacs TO; Campbell D; Richter J; Haber M; Jennings DE; Rose P
    Aliment Pharmacol Ther; 1999 Jul; 13(7):959-67. PubMed ID: 10383532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
    Dobrilla G; Capurso L
    Recenti Prog Med; 2000 Apr; 91(4):191-210. PubMed ID: 10804753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Gastric protection and treatment with low-dose aspirin].
    Agustí-Escasany A; Vallano-Ferraz A
    Med Clin (Barc); 2006 Feb; 126(6):232-3. PubMed ID: 16510098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.